FDA issues final guidance on rare disease drug development
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsProduct developmentUnited StatesRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsProduct developmentUnited States